319 related articles for article (PubMed ID: 19350631)
1. Limits of CD133 as a marker of glioma self-renewing cells.
Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF
Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679
[TBL] [Abstract][Full Text] [Related]
3. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.
Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN
Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330
[TBL] [Abstract][Full Text] [Related]
4. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
[TBL] [Abstract][Full Text] [Related]
5. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
6. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells.
Niu CS; Li DX; Liu YH; Fu XM; Tang SF; Li J
Oncol Rep; 2011 Sep; 26(3):593-601. PubMed ID: 21573506
[TBL] [Abstract][Full Text] [Related]
7. The pathological characteristics of glioma stem cell niches.
He H; Li MW; Niu CS
J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
[TBL] [Abstract][Full Text] [Related]
8. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma].
Bi CL; Fang JS; Chen FH; Wang YJ; Wu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
[TBL] [Abstract][Full Text] [Related]
10. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
[TBL] [Abstract][Full Text] [Related]
11. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
12. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
14. Study on the proliferation and drug-resistance of human brain tumor stem-like cells.
Qin K; Jiang X; Zou Y; Wang J; Qin L; Zeng Y
Cell Mol Neurobiol; 2010 Aug; 30(6):955-60. PubMed ID: 20526804
[TBL] [Abstract][Full Text] [Related]
15. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
16. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
17. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
Li MW; Niu CS
Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
[TBL] [Abstract][Full Text] [Related]
18. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
20. Biology of glioma cancer stem cells.
Park DM; Rich JN
Mol Cells; 2009 Jul; 28(1):7-12. PubMed ID: 19655094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]